Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection
Status:
Recruiting
Trial end date:
2022-07-29
Target enrollment:
Participant gender:
Summary
This clinical trial will study the safety and efficacy of COVID-19-specific T cells when
given as treatment to adult patients (age ≥ 18 years) with a COVID-19 infection. This
immunologic treatment is aimed at patients, who are at high risk of progression due to their
advanced age, or other underlying health conditions. The outcomes of patients receiving the T
cells (Arm A) will be compared to patients treated with standard of care (Arm B).